.png){kind=icon}
返回
Roxadustat: First Global Approval
.png){kind=icon}
OA
AI
DOI：10.1007/s40265-019-01077-1.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Roxadustat (Ai Rui Zhuo((R)) in China) is an orally administered, small molecule hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that is being developed by FibroGen, in collaboration with Astellas and AstraZeneca, for the treatment of anaemia in patients with dialysis-dependent chronic kidney disease (CKD), non-dialysis-dependent CKD and in patients with myelodysplastic syndromes. The drug reversibly binds to and inhibits HIF-prolyl hydroxylase enzymes that are responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. Inhibition of these enzymes reduces HIF breakdown and promotes HIF activity, leading to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability and increases haemoglobin levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. Roxadustat is approved in China and is under regulatory review in Japan for the treatment of anaemia in patients with dialysis-dependent CKD. Studies are underway to investigate long-term cardiovascular outcomes with roxadustat versus placebo (for non-dialysis-dependent CKD) or standard of care (for dialysis-dependent CKD). This article summarizes the milestones in the development of roxadustat leading to this first approval.
Keyword:
PROLYL HYDROXYLASE
ANEMIA
FG-4592
INHIBITOR
ERYTHROPOIESIS
PHASE-2
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
.png){kind=icon}
分享收藏
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients靶向缺氧诱导因子治疗慢性肾脏病贫血OAAI
OAAI分享收藏Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6-to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy StudyRoxadustat (FG-4592) 与Epoetin Alfa治疗维持性血液透析患者的贫血: 2期，随机，6至19周，开放标签，主动比较，剂量范围，安全性和探索性疗效研究OAAI
OAAI分享收藏
查看更多内容